Reviva Pharmaceuticals I...

AI Score

XX

Unlock

0.84
-0.06 (-6.67%)
At close: Apr 25, 2025, 3:59 PM
0.85
0.36%
After-hours: Apr 25, 2025, 05:42 PM EDT

Company Description

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases.

The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.

It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity.

The company is headquartered in Cupertino, California.

Reviva Pharmaceuticals Inc.
Reviva Pharmaceuticals  Inc. logo
Country United States
IPO Date Oct 18, 2018
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Dr. Laxminarayan Bhat Ph.D.

Contact Details

Address:
19925 Stevens Creek Boulevard
Cupertino, California
United States
Website https://revivapharma.com

Stock Details

Ticker Symbol RVPH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001742927
CUSIP Number 76152G100
ISIN Number US76152G1004
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Laxminarayan Bhat Ph.D. Founder, Chief Executive Officer, President & Director
Narayan Prabhu Chief Financial Officer

Latest SEC Filings

Date Type Title
Apr 03, 2025 S-8 Filing
Apr 03, 2025 10-K Annual Report
Mar 31, 2025 NT 10-K Filing
Mar 31, 2025 8-K Current Report
Feb 18, 2025 8-K Current Report
Feb 18, 2025 4 Filing
Feb 18, 2025 4 Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 07, 2025 SCHEDULE 13G/A [Amend] Filing
Jan 31, 2025 SCHEDULE 13D/A [Amend] Filing